StockWireNews
Nasdaq Breakout Watch: Low Float (LIXT) Is Today's Must-See Alert (Float Under 2Mn Shares)
October 26th
Greetings Readers,
Well that was something to behold...
Alerted on Monday night, my latest breakout idea caught the attention of the market big-time come Tuesday morning.
After closing Monday's session at $.58, the Nasdaq low float profile absolutely rocketed the following day to a high of $2.08.
With the backing from some incredible news, my alert exploded for a short term run of approximately 258% in under 24 hours!
That's what can happen when two potential catalysts pair together like a low float with positive company news.
Which is a good reason why you should clear your schedule for my next breakout idea arriving right now.
What do I mean by that? Simple. This is another low float idea.
As we saw earlier this week, a low float can provide the right environment to see explosive volatility intraday and/or short term.
Could we stand witness to another major mover today?
Listen. I'm not going to drown you in details this second because may already be running low to pull up this company profile:
*LIXTE Biotechnology Holdings, Inc. (LIXT)*
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors. The Company’s innovative approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for patients.
This Summer LIXT Announces 1-10 Reverse Split
Earlier in 2023, LIXT made an important announcement in regards to their share structure.
Check it out:
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse St-ock Split of its Common St-ock...
PASADENA, CA, June 02, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) announced today that it will effect a 1-for-10 reverse st-ock split of its issued and outstanding common st-ock...
Read the full article here.
LIXT's Reverse Split Creates Tiny Float/Volatile Potential
According to the Yahoo Finance website, LIXT now has a very low float.
The website reports this profile to have roughly 1.96Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company news towards the end of 2023 provide LIXT with a breakout spark?
-----
LIXT Company Breakdown - Transforming Cancer Treatment With Protein Phosphatase 2A Inhibitors
Unveiling the first of a novel class of therapeutic agents.
Lixte has developed a first-in-class enhancer of chemotherapy and immunotherapy.
In recent years, the field of cancer treatment has undergone remarkable advancement with the introduction of immunotherapy. This approach has revolutionized the landscape of cancer care.
Both chemotherapy, and immunotherapy are treatment modalities that offer broad applicability to many types and stages of cancer, with the potential to benefit a wide range of patients. The company's lead molecule LB-100 has shown remarkable synergy with chemotherapy and immunotherapy in a range of pre-clinical models.
Chemotherapy & Immunotherapy: Shared Potential, Common Challenges
Chemotherapy and immunotherapy face common challenges that have limited their success rates:
Limited efficacy: The efficacy of these approaches is limited by the resistance of cancer cells, both intrinsic and acquired.
Toxicity: The potential for side effects can restrict the dosage or duration of treatment and, consequently, impact the overall efficacy.
Pioneering A Novel Class Of Cancer Therapy
